Search
for

    Learn

    5 / 65 results

      learn Hydrocortisone

      a synthetic cortisol used for anti-inflammatory effects

      learn Exosomes

      Microscopic delivery system that sends growth-promoting signals to hair follicles

      learn Melatonin

      hormone commonly taken for sleep aid has some topical benefits for hair

      learn Caffeine

      the stimulant you know and love can be used topically to stimulate hair

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community Fats on your Head to Stop Hair Loss?

      in Research/Science  138 upvotes 2 years ago
      The conversation discusses the potential of long-chain unsaturated fatty acids, like oleic and linoleic acid, as an additional treatment for hair loss, which may inhibit the enzyme responsible for converting testosterone to DHT and promote hair growth. Users humorously suggest using oils topically and discuss other hair loss treatments, but the main focus is on the science behind fatty acids and their role in hair health.

      community Minoxidil is a 5ar inhibitor according to research

      in Research/Science  149 upvotes 4 months ago
      Minoxidil may inhibit androgen receptors and affect hormonal pathways, potentially explaining its effectiveness in treating androgenetic alopecia (AGA). Users discuss its varying effectiveness on scalp versus facial hair and note fewer side effects with topical use compared to oral.

      community Making your own RT1640 in China

      in Research/Science 4 years ago
      RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 3 years ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.